EGFR Mutation

15 registered clinical trials studyying EGFR Mutation — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer NCT07285148	Beijing Pearl Biotechnology Limited Liability Company	Phase 1 / Phase 2
Not Yet Recruiting	Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety St NCT07365410	Tianjin Medical University Cancer Institute and Hospital	Phase 2
Enrolling By Invitation	Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance NCT07122882	Chang Gung Memorial Hospital	—
Not Yet Recruiting	High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated NCT06971406	Qiming Wang	Phase 2
Completed	A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken To NCT06360211	Bayer	Phase 1
Completed	A Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When The NCT06348888	Bayer	Phase 1
Completed	A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Togeth NCT06378658	Bayer	Phase 1
Completed	A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These NCT06329895	Bayer	Phase 1
Completed	A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male Participants NCT06221475	Bayer	Phase 1
Completed	Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE) NCT05465343	Peking Union Medical College	Phase 2
Active Not Recruiting	First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With M NCT05099172	Bayer	Phase 1 / Phase 2
Unknown	Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation NCT03486496	Fujian Cancer Hospital	Phase 2
Unknown	Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer NCT01951469	Sun Yat-sen University	Phase 3
Unknown	Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients NCT02226757	Amsterdam UMC, location VUmc	Phase 2
Unknown	Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC NCT02140333	The First Affiliated Hospital of Guangzhou Medical University	Phase 3